Antibody-Mediated Rejection: Addressing the Underlying Issues for Improved Patient Outcomes

136-20-784-SM ATC Title Slide_16x9

Activity Overview

The goal of this activity is to provide education about AMR treatment principles, guidelines, and emerging therapies. Faculty will discuss the genesis of alloantibody production and how it contributes to graft loss, as well as unmet needs in AMR therapies. An experienced patient with AMR provides insights for transplant clinicians to consider when treating their patients with AMR.

1.00 CE Credit(s)
Expires: August 6, 2021

Target Audience

This activity is intended for clinicians actively engaged in managing antibody-mediated rejection (AMR) in transplant patients, including transplant physician, surgeons, NPs, and PAs with an interest in transplant

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Summarize the pathophysiology of antibody-mediated rejection (AMR), including the role of the complement system and cytokine pathways in disease pathogenesis
  • Evaluate the efficacy and safety data supporting existing and emerging treatment options for AMR, including anti-complement and anti-cytokine strategies
  • Select appropriate treatments for patients with AMR to improve allograft survival

Activity Faculty

Robert Montgomery 2019 photo_Crop

Robert A. Montgomery, MD, DPhil, FACS (Chair)

Professor of Surgery
, NYU Langone Transplant Institute
New York, NY


Arjang Djamali, MD, MS, FASN

Professor, Medicine and Surgery
Head, Division of Nephrology
Department of Medicine
University of Wisconsin
School of Medicine and Public Health
Madison, WI


Stanley C. Jordan, MD, FASN, FAST

Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Professor, Pediatrics & Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Michael Kronman (Patient)